Multiple Myeloma Research Foundation
Signal active
Investment Firm
Overview
N/A
Highlights
Founded
1998
Industry
Health Care
Employees
51-100
Investment
5
Lead Investment
4
Exits
2
Stages
Early Stage Venture
Investor Type
N/A
Location
Norwalk, Connecticut, United States, North America
Contact Information
Social
Profile Resume
Multiple Myeloma Research Foundation, established in 1998 and headquartered in United States, North America., specializes in Early Stage Venture investments across Health Care, Medical, Hospital, Biotechnology, Clinical Trials, Financial Services, Venture Capital, Finance, FinTech, Business Development. The organization boasts a portfolio of 5 investments, with an average round size of $17.7M and 2 successful exits. Their recent investments include Mount Sinai Health System, Triumvira Immunologics, B Capital, Leaps by Bayer, ATEM Capital Fund LP. The highest investment round they participated in was $3.4B. Among their most notable exits are Mount Sinai Health System and Triumvira Immunologics. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Multiple Myeloma Research Foundation has made 5 investments. Their most recent investment was on Nov 02, 2023, when Mount Sinai Health System raised $7.0M.
Multiple Myeloma Research Foundation has made 1 diversity investments. Their most recent diversity investment was on Jan 06, 2011, when Karyopharm Therapeutics raised $1.0M.
investments
5
Diversity investments
1
Lead investments
4
Number of exits
2
Investments
5
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jan 06, 2011 | Karyopharm Therapeutics | Health Care | 1.0M |
| Jan 06, 2011 | Epizyme | Biotechnology | 1.0M |
| Mar 17, 2022 | Triumvira Immunologics | Biotechnology | 45.0M |
| Nov 02, 2023 | Mount Sinai Health System | Health Care | 7.0M |
EpizymeExits
2
Funding Timeline
Funding rounds
5
Investors
0
Funds
0
Funding Rounds
5
Multiple Myeloma Research Foundation has raised 5 rounds. Their latest funding was raised on Nov 02, 2023 from a Grant - Mount Sinai Health System round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jan 06, 2011 | Grant - Epizyme | - | 1.0M | - |
| Mar 17, 2022 | Series A - Triumvira Immunologics | - | 45.0M | - |
| Nov 02, 2023 | Grant - Mount Sinai Health System | - | 7.0M | - |
| Nov 02, 2023 | Grant - Mount Sinai Health System | - | 7.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Apr 11, 2024
NKyTribune - Notre Dame to hold its first Craig Milburn (softball) Showcase benefitting Multiple Myeloma research - NKyTribune
News
Nov 07, 2023
Myeloma Research News - Foundation awards $21M in grants supporting multicenter research
News
Nov 02, 2023
Mount Sinai - Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the ...
Funding Round
Nov 02, 2023
Mount Sinai Health System raised $7000000 on 2023-11-02 in Grant
Funding Round
Nov 02, 2023
Mount Sinai Health System raised $7000000 on 2023-11-02 in Grant
Funding Round
Mar 17, 2022
Triumvira Immunologics raised $45000000 on 2022-03-17 in Series A